Web Analytics

3 Latest Announced Rounds

  • $3,500,000
    Seed

    1 Investors

    Technology, Information and Internet
    Dec 20th, 2024
  • $5,619,170
    Series B

    1 Investors

    Research Services
    Dec 20th, 2024
  • $8,000,000
    Unknown

    5 Investors

    Computer & Network Security
    Dec 20th, 2024
$671.88M Raised in 44 Funding Rounds in the past 7 Days - View All

Funding Round Profile

Neurenati Therapeutics

start up
Canada - Montréal, Québec
  • 01/03/2024
  • Seed
  • $1,200,000

Neurenati develops novel therapies for GI rare diseases


Related People

Maxime RangerFounder

Maxime Ranger Canada - Greater Montreal Metropolitan Area

Serial entrepreneur who turned into venture capitalist in the life science space, specialized in the drug development: oncology, hepatology, gastroenterology and metabolic conditions, such as NASH, Prader-Willi Syndrome, type-2 diabetes and obesity. MBA, Ph.D. chemist with a scientific background in Material Sciences, more particularly in polymer chemistry. Two postdoc internships oriented to drug delivery, formulation development and nanolithography. Experience now extended to due diligence investigation, drug hunting and start-up financing. Co-authors of 30+ scientific publications in international peer-reviewed journals and co-inventors of 9 PCT-patented technologies.

Specialties: CMC, formulation development, drug delivery, IND-enabling preclinical studies, clinical development strategies (Phase I & II). Pre-Seed, Seed, Series A/B Fundraising, Corporate affairs, licensing activities and IP strategy.